ClinicalTrials.gg
CompletedNCT00798759Updated Jun 1, 2012Results posted

Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN

A Phase 4 interventional study of Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) and Latanoprost ophthalmic solution 0.005% (XALATAN®) in Open-angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-01.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
11th of 45
236 · median 135
Started
2008
with 7 others
Phase 4
22 of 46
2 open now
Registered
20th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 11th largest by enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2008, is one of 22 in phase 4, and was the 20th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension

Keywords

  • Open-angle glaucoma
  • Ocular hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older.
  • Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.
  • Intraocular pressure (IOP) controlled with BAK (benzalkonium chloride) preserved IOP-lowering medication for 1 year, with last 6 months on XALATAN® monotherapy.
  • Best corrected visual acuity of -0.6 logMAR or better in each eye.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Treatment with BAK preserved artificial tears within 30 days of Visit 1.
  • Known or suspected Sjogren's disease.
  • Uncontrolled IOP.
  • History or evidence of infectious or inflammatory ocular conditions.
  • Progressive retinal or optic nerve disease.
  • Ocular laser surgery within 3 months of Visit 1.
  • Keratorefractive ocular laser procedures, corneal surgery or surgery to the corneal surface within 1 year of Visit 1.
  • Current use of punctal plugs or punctal cautery.
  • Use of systemic medications that has not been stable for 30 days prior to Visit 1.
  • Use of contact lens within 30 days of Visit 1.
  • Other protocol-defined exclusion criteria may apply.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    Travoprost

    One drop self-administered in the study eye(s) once daily at night for 12 weeks

    Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

  • Active comparator
    Latanoprost

    One drop self-administered in the study eye(s) once daily at night for 12 weeks

    Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)

Interventions

  • DrugTravoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

    Drug page: Travoprost

    Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.

    Also known as: TRAVATAN Z®

  • Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.

    Also known as: XALATAN®

06

What researchers measure

Primary outcomes

  1. Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT)

    Tear film break-up time was assessed by the same examiner both visits using the same slitlamp/settings. Examiner instilled fluorescein onto the patient's eye, after which the patient blinked several times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to time the occurrence of the first break in the fluorescein film. Three consecutive measurements were taken and averaged for actual TBUT. TBUT at Baseline (Day 0) was subtracted from TBUT at 12 weeks (Day 84) and reported as change. A higher number represents a lengthening in the tear film break up time.

    Time frame: Day 0, Day 84

Secondary outcomes

  1. Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

    The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 12-week OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.

    Time frame: Day 0, Day 84

07

Results

Posted Apr 23, 2012
Limitations and caveats
The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)

Participant flow

Patients were recruited from 22 US study centers. Eligible patients having a diagnosis of open-angle glaucoma or ocular hypertension and on XALATAN® monotherapy for six months prior to Visit 1 were enrolled.

Participant flow — Overall Study
MilestoneTravoprostLatanoprost
Started117119
Completed109106
Not completed813
Withdrew: Adverse event33
Withdrew: Lost to follow-up11
Withdrew: Protocol violation48
Withdrew: Other01

Outcome measures

PrimaryMean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT)

Tear film break-up time was assessed by the same examiner both visits using the same slitlamp/settings. Examiner instilled fluorescein onto the patient's eye, after which the patient blinked several times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to time the occurrence of the first break in the fluorescein film. Three consecutive measurements were taken and averaged for actual TBUT. TBUT at Baseline (Day 0) was subtracted from TBUT at 12 weeks (Day 84) and reported as change. A higher number represents a lengthening in the tear film break up time.

Time frame:
Day 0, Day 84
Reported as:
Mean · Seconds
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT)
SecondsTravoprostLatanoprost
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT)0.7 ± 0.10.6 ± 0.2
SecondaryMean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score

The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 12-week OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.

Time frame:
Day 0, Day 84
Reported as:
Mean · Units on a scale
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
Units on a scaleTravoprostLatanoprost
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score-1.9 ± 1.20.6 ± 1.5

Adverse events

Collected over Adverse events were collected for the duration of the study: 22 December 2008 to 20 May 2009.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travoprost—1/117 (0.9%)7/117 (6%)
Latanoprost—2/119 (1.7%)3/119 (2.5%)
Most frequent serious events
Most frequent serious events
EventTravoprostLatanoprost
Blood urine presentInvestigations1/1170/119
DehydrationMetabolism and nutrition disorders0/1171/119
Coronary Arterial Stent InsertionSurgical and medical procedures0/1171/119
Most frequent other events
Most frequent other events
EventTravoprostLatanoprost
Dry EyeEye disorders7/1173/119

Baseline characteristics

Age Continuous
Age Continuous(years)TravoprostLatanoprostTotal
Mean66.3 ± 12.169.0 ± 10.467.6 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)TravoprostLatanoprostTotal
Female6671137
Male433578
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2008
First posted
Nov 26, 2008
Start
Dec 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Apr 23, 2012
Last update
Jun 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00798759
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Nov 26, 2008
Start date
Dec 2008
Primary completion
May 2009
Completion
May 2009
Results posted
Apr 23, 2012
Last update
Jun 1, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion